A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
Clinical trial NCT02717624 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02717624
- Sponsor
- Acerta Pharma BV
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-20
- Primary completion
- 2022-06-15
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.